European equities traded in the US as American depositary receipts were heading lower late Tuesday morning, declining 0.27% to 1,415.23 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion Biotech (EVAX), which climbed 5.9% and 3.4% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and internet advertising firm Criteo (CRTO), which advanced 2% and 1.4% respectively.
The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Novo Nordisk (NVO), which dropped 5.3% and 3.3% respectively. They were followed by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which lost 2.6% and 2.5%, respectively.
From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which rose 3.3% and 2.5% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and financial services company Lloyds Banking Group (LYG), which were up 2.2% and 1.6% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and biotech firm Autolus Therapeutics (AUTL), which fell 13% and 7.4% respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group plc (MREO) and Bicycle Therapeutics (BCYC), which were down 7.6% and 5.1% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。